A citation-based method for searching scientific literature

Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
Times Cited: 102







List of co-cited articles
843 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
841
56

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
47

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
46

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
P Sivaramakrishna Rachakonda, Ismail Hosen, Petra J de Verdier, Mahdi Fallah, Barbara Heidenreich, Charlotta Ryk, N Peter Wiklund, Gunnar Steineck, Dirk Schadendorf, Kari Hemminki,[...]. Proc Natl Acad Sci U S A 2013
205
39

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
505
35

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Sabine Spiegl-Kreinecker, Daniela Lötsch, Bahil Ghanim, Christine Pirker, Thomas Mohr, Magdalena Laaber, Serge Weis, Alfred Olschowski, Gerald Webersinke, Josef Pichler,[...]. Neuro Oncol 2015
69
47

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Marianne Labussière, Blandine Boisselier, Karima Mokhtari, Anna-Luisa Di Stefano, Anais Rahimian, Marta Rossetto, Pietro Ciccarino, Olivier Saulnier, Rosina Paterra, Yannick Marie,[...]. Neurology 2014
123
32

TERT promoter mutations in primary and secondary glioblastomas.
Naosuke Nonoguchi, Takashi Ohta, Ji-Eun Oh, Young-Ho Kim, Paul Kleihues, Hiroko Ohgaki. Acta Neuropathol 2013
144
31

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
925
29

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
27

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Hideyuki Arita, Yoshitaka Narita, Shintaro Fukushima, Kensuke Tateishi, Yuko Matsushita, Akihiko Yoshida, Yasuji Miyakita, Makoto Ohno, V Peter Collins, Nobutaka Kawahara,[...]. Acta Neuropathol 2013
219
26

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Robert J A Bell, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci,[...]. Science 2015
285
24

TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mohamed Ali Mosrati, Annika Malmström, Malgorzata Lysiak, Adam Krysztofiak, Martin Hallbeck, Peter Milos, Anna-Lotta Hallbeck, Charlotte Bratthäll, Michael Strandéus, Marie Stenmark-Askmalm,[...]. Oncotarget 2015
62
37

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
23

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
21

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
M Labussière, A L Di Stefano, V Gleize, B Boisselier, M Giry, S Mangesius, A Bruno, R Paterra, Y Marie, A Rahimian,[...]. Br J Cancer 2014
101
20

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
20

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Barbara Heidenreich, Eduardo Nagore, P Sivaramakrishna Rachakonda, Zaida Garcia-Casado, Celia Requena, Victor Traves, Jürgen Becker, Nadem Soufir, Kari Hemminki, Rajiv Kumar. Nat Commun 2014
114
19

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
19

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
18

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Patrick J Killela, Christopher J Pirozzi, Patrick Healy, Zachary J Reitman, Eric Lipp, B Ahmed Rasheed, Rui Yang, Bill H Diplas, Zhaohui Wang, Paula K Greer,[...]. Oncotarget 2014
159
18

Specific association of human telomerase activity with immortal cells and cancer.
N W Kim, M A Piatyszek, K R Prowse, C B Harley, M D West, P L Ho, G M Coviello, W E Wright, S L Weinrich, J W Shay. Science 1994
17

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Klaus G Griewank, Rajmohan Murali, Joan Anton Puig-Butille, Bastian Schilling, Elisabeth Livingstone, Miriam Potrony, Cristina Carrera, Tobias Schimming, Inga Möller, Marion Schwamborn,[...]. J Natl Cancer Inst 2014
147
17

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Christian Koelsche, Felix Sahm, David Capper, David Reuss, Dominik Sturm, David T W Jones, Marcel Kool, Paul A Northcott, Benedikt Wiestler, Katja Böhmer,[...]. Acta Neuropathol 2013
185
16


TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Barbara Heidenreich, P Sivaramakrishna Rachakonda, Ismail Hosen, Florian Volz, Kari Hemminki, Astrid Weyerbrock, Rajiv Kumar. Oncotarget 2015
54
29

The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Rui Batista, Adriana Cruvinel-Carloni, João Vinagre, Joana Peixoto, Telmo A Catarino, Nathalia Cristina Campanella, Weder Menezes, Aline Paixão Becker, Gisele Caravina de Almeida, Marcus M Matsushita,[...]. Int J Cancer 2016
35
45

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu,[...]. Acta Neuropathol Commun 2016
110
16

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
15

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
15

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
251
15

TERT promoter mutations in cancer development.
Barbara Heidenreich, P Sivaramakrishna Rachakonda, Kari Hemminki, Rajiv Kumar. Curr Opin Genet Dev 2014
140
14

TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.
Helena Pópulo, Paula Boaventura, João Vinagre, Rui Batista, Adélia Mendes, Regina Caldas, Joana Pardal, Filomena Azevedo, Mrinalini Honavar, Isabel Guimarães,[...]. J Invest Dermatol 2014
76
18

Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.
Xiaoli Liu, Guojun Wu, Yuan Shan, Christian Hartmann, Andreas von Deimling, Mingzhao Xing. Cell Cycle 2013
95
14

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
14

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
296
14

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
372
14

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
T Liu, N Wang, J Cao, A Sofiadis, A Dinets, J Zedenius, C Larsson, D Xu. Oncogene 2014
155
13

Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma.
Chul-Kee Park, Se-Hoon Lee, Ji Young Kim, Ja Eun Kim, Tae Min Kim, Soon-Tae Lee, Seung Hong Choi, Sung-Hye Park, Il Han Kim. Oncotarget 2014
36
36

A survey of telomerase activity in human cancer.
J W Shay, S Bacchetti. Eur J Cancer 1997
13

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
13

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Jean Charles Nault, Maxime Mallet, Camilla Pilati, Julien Calderaro, Paulette Bioulac-Sage, Christophe Laurent, Alexis Laurent, Daniel Cherqui, Charles Balabaud, Jessica Zucman-Rossi. Nat Commun 2013
359
13

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Sumit Borah, Linghe Xi, Arthur J Zaug, Natasha M Powell, Garrett M Dancik, Scott B Cohen, James C Costello, Dan Theodorescu, Thomas R Cech. Science 2015
186
13

TERT promoter mutations in melanoma survival.
Eduardo Nagore, Barbara Heidenreich, Sívaramakrishna Rachakonda, Zaida Garcia-Casado, Celia Requena, Virtudes Soriano, Christoph Frank, Victor Traves, Esther Quecedo, Josefa Sanjuan-Gimenez,[...]. Int J Cancer 2016
66
19

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
891
13

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
12

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
353
12

Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Kunitoshi Chiba, Joshua Z Johnson, Jacob M Vogan, Tina Wagner, John M Boyle, Dirk Hockemeyer. Elife 2015
139
12

Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc.
Dakang Xu, Julie Dwyer, He Li, Wei Duan, Jun-Ping Liu. J Biol Chem 2008
101
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.